BlackRock, Inc. files a Schedule 13G reporting beneficial ownership of 1,804,099 shares of Lenz Therapeutics common stock. The filing shows 1,804,099 shares beneficially owned, representing 5.8% of the class as of 03/31/2026, with sole voting power of 1,782,990 shares.
Positive
None.
Negative
None.
Insights
BlackRock holds a reported 1.8M-share stake (5.8%) in Lenz Therapeutics as of 03/31/2026.
BlackRock's Schedule 13G lists 1,804,099 shares beneficially owned and a sole dispositive power of the same amount, indicating control over disposition decisions as of 03/31/2026. The filing is typical for passive institutional holdings.
Watch future filings for any conversion to a Schedule 13D or Form 4 disclosures; timing not specified in the provided excerpt.
This filing documents institutional disclosure and voting stakes, not a change in governance.
The filing lists sole voting power of 1,782,990 shares and states various persons may receive dividends or proceeds. It does not identify any single person with >5% beneficial interest beyond BlackRock's reported stake.
Follow periodic amendments or proxy filings for any shifts in stated voting or dispositive arrangements.
Key Figures
Shares beneficially owned:1,804,099 sharesPercent of class:5.8%Sole voting power:1,782,990 shares+1 more
4 metrics
Shares beneficially owned1,804,099 sharesas of 03/31/2026
Percent of class5.8%percent of outstanding common stock
Sole voting power1,782,990 sharesshares as to which filer has sole power to vote
Sole dispositive power1,804,099 sharesshares as to which filer has sole power to dispose
Key Terms
Schedule 13G, beneficially owned, sole dispositive power, investment company
4 terms
Schedule 13Gregulatory
"In accordance with SEC Release No. 34-39538 (January 12, 1998)"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially ownedfinancial
"reflects the securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive powerregulatory
"Sole power to dispose or to direct the disposition of: 1804099"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
investment companyregulatory
"A listing of the shareholders of an investment company registered under the Investment Company Act"
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
LENZ THERAPEUTICS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
52635N103
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
52635N103
1
Names of Reporting Persons
BlackRock, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,782,990.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,804,099.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,804,099.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.8 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
LENZ THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075
Item 2.
(a)
Name of person filing:
BlackRock, Inc.
In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)
Address or principal business office or, if none, residence:
BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)
Citizenship:
See Item 4 of Cover Page
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
52635N103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
1804099
(b)
Percent of class:
5.8 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
1782990
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
1804099
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of LENZ THERAPEUTICS, INC.. No one person's interest in the common stock of LENZ THERAPEUTICS, INC. is more than five percent of the total outstanding common shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Exhibit 99
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does BlackRock (LENZ) report on Schedule 13G?
BlackRock reports beneficial ownership of 1,804,099 shares of common stock, representing 5.8%. The filing states these figures are as of 03/31/2026 and shows sole dispositive power over the same share count.
Does BlackRock have voting control of LENZ shares reported?
BlackRock reports sole voting power for 1,782,990 shares. The Schedule 13G lists sole voting and sole dispositive powers separately, indicating voting authority over most of the reported stake.
Is this Schedule 13G filing an active takeover signal for LENZ?
No, this filing is a passive disclosure of holdings rather than an acquisition proposal. Schedule 13G typically reports passive institutional ownership and does not itself indicate a takeover intent.
As of what date are the ownership figures in the LENZ filing reported?
The ownership figures are reported as of 03/31/202604/27/2026, which reflects the reporting date and signature date provided in the excerpt.
Who signed the Schedule 13G for BlackRock in the LENZ filing?
The Schedule 13G excerpt is signed by Spencer Fleming, listed as Managing Director, with the signature date of 04/27/2026.
